# US 2015/0147340 A1 · Therapeutic methods for peritoneal carcinomatosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147340 A1
- Document ID: US20150147340A1
- Status: Published application
- Kind: A1
- Application number: 14/389,315
- Filed: 2013-03-12
- Published: 2015-05-28
- Earliest claimed: 2012-03-30
- Applicants: FibroGen, Inc.
- Inventors: Goli Samimi; Kim Moran-Jones
- Web page: https://patentgrep.com/patent/US20150147340A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate}
- C12N 15/1136: {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 2310/11: Antisense
- C12N 2310/12: catalytic nucleic acids, e.g. ribozymes
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/531: Stem-loop; Hairpin
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Described herein are methods and medicaments useful for treating peritoneal carcinomatosis by administering anti-CTGF agents, particularly anti-CTGF antibodies. Methods for prognosing individuals with perinoteal carcinomatosis are also provided. In one aspect, the present invention provides a method of treating a subject with peritoneal carcinomatosis, the method comprises the administration to the subject of an effective amount ohm anti-connective tissue growth factor (CTGF) agent, thereby treating the peritoneal carcinomatosis. In some embodiments, the peritoneal carcinomatosis results from a cancer selected from the group consisting of gall bladder cancer, bile duct cancer, liver cancer, colon cancer, cancer of the appendix, ovarian cancer, fallopian tube cancer, bladder cancer, pancreatic cancer, mesothelioma, rectal cancer, small bowel cancer and stomach cancer. In particular embodiments, the cancer is ovarian cancer. In further embodiments, the ovarian cancer is classified as serous, clear cell, mucinous or endometrioid.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A method of treating mesothelioma in a subject in need thereof, the method comprising administering to the subject an effective amount of an anti-connective tissue growth factor (CTGF) agent, thereby treating the mesothelioma.

### Claim 22 (depends on 21)

The method of claim 21, wherein the anti-CTGF agent is an antibody, antibody fragment or antibody mimetic.

### Claim 23 (depends on 22)

The method of claim 22, wherein the anti-CTGF agent is an antibody.

### Claim 24 (depends on 23)

The method of claim 23, wherein the anti-CTGF antibody is identical to the antibody produced by the cell line identified by ATCC Accession No. PTA-6006.

### Claim 25 (depends on 21)

The method of claim 21, wherein the anti-CTGF agent is an anti-CTGF oligonucleotide.

### Claim 26 (depends on 25)

The method of claim 25, wherein the anti-CTGF oligonucleotide is an antisense oligonucleotide, siRNA, ribozyme or shRNA.

### Claim 27 (depends on 21)

The method of claim 21, further comprising the administration of another therapeutic modality selected from the group consisting of chemotherapy, immunotherapy, gene therapy, surgery, radiotherapy, or hyperthermia.
